Search

Displaying results 6441 - 6450 of 10000 in total
  1. Drug

    Autologous Non-Hematopoietic Peripheral Blood Stem Cells

    go.drugbank.com/drugs/DB15867
    Investigational

    Autologous non-hematopoietic peripheral blood stem cells have been created into a formulation for use in a clinical trial (NCT04473170) by the Abu Dhabi Stem Cells Center.

  2. Drug

    ORG-34517

    go.drugbank.com/drugs/DB05423
    Investigational

    It has potential to treat a number of diseases such as Cushing’s disease, hypertension, diabetes, glaucoma etc, in which the activity of metabolites corticosterone and cortisol is high.

  3. Drug

    Glucose-6-Phosphate

    go.drugbank.com/drugs/DB03581
    Experimental

    An ester of glucose with phosphoric acid, made in the course of glucose metabolism by mammalian and other cells. … It is a normal constituent of resting muscle and probably is in constant equilibrium with fructose-6-phosphate. (Stedman, 26th ed)

  4. Drug

    Azimilide

    go.drugbank.com/drugs/DB04957
    Investigational

    Azimilide is an investigational class III anti-arrhythmic drug that blocks fast and slow components of the delayed rectifier cardiac potassium channels.

  5. Drug

    DP-b99

    go.drugbank.com/drugs/DB05820
    Investigational

    DP-b99 is a newly developed lipophilic, cell permeable derivative of BAPTA (1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid), that is under development as a neuroprotectant for the potential treatment

  6. Drug

    19-Nor-5-androstenedione

    go.drugbank.com/drugs/DB01443
    ExperimentalIllicit

    It is regulated in the United States as a schedule III controlled substance, and prohibited by the World Anti-Doping Agency for use in competitive sports. … 19-Nor-5-andorstenedione is a prohormone which has the potential to affect bodily levels of testosterone once metabolized in vivo.

  7. Drug

    Prinomastat

    go.drugbank.com/drugs/DB05100
    Investigational

    As a lipophilic agent, prinomastat crosses the blood-brain barrier. … Prinomastat is a synthetic hydroxamic acid derivative with potential antineoplastic activity.

  8. Drug

    Venetoclax

    go.drugbank.com/drugs/DB11581
    ApprovedInvestigational

    Venetoclax is a BCL-2 inhibitor that was initially approved by the FDA in April 2016 [FDA label]. … A new indication was approved in 2018 for the treatment patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), with or without 17p deletion, who have received at least one

    Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index
  9. Drug

    Anti-SARS-CoV-2 REGN-COV2

    go.drugbank.com/drugs/DB15691
    Investigational

    including contacts of an infected individual. … Anti-SARS-COV-2 REGN-COV2 is a combination of novel antibodies designed by Regeneron for both the prevention and treatment of SARS-COV-2, the virus that causes COVID-19.

  10. Drug

    SARS-CoV-2 Sclamp

    go.drugbank.com/drugs/DB15849
    Investigational

    The vaccine was developed using UQ’s rapid response ‘molecular clamp’ vaccine platform that locks surface proteins in a configuration that allows more robust immune responses, in combination with a well-established … Preclinical trials showed the vaccine candidate produced high levels of neutralizing antibodies, and induced a strong T-cell response.